SynthesisEuropean journal of preventive cardiology2018
Association between progestin-only contraceptive use and cardiometabolic outcomes: A systematic review and meta-analysis.
Synthesis in European journal of preventive cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 5 syntheses or guidelines pooled it, 116 citations in OpenAlex.
- Contraceptive use among women with inflammatory bowel disease: An updated systematic review.Contraception · 2025Pooled it
- Investigation and management of resistant hypertension: British and Irish Hypertension Society position statement.Journal of human hypertension · 2025Guideline
- Association of Hormonal Contraceptive Use With Adverse Health Outcomes: An Umbrella Review of Meta-analyses of Randomized Clinical Trials and Cohort Studies.JAMA network open · 2022Pooled it
- Clinical practice guideline of the Interamerican Society of Cardiology on primary prevention of cardiovascular disease in women.Archivos de cardiologia de Mexico · 2022Guideline
- Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review.BMJ (Clinical research ed.) · 2020Pooled it
- Efficacy and Safety of 48-Week Low-Dose Dienogest Treatment in Patients with Endometriosis-Associated Dysmenorrhea: A Randomized, Open-Label, Parallel-Group Trial.Advances in therapy · 2025Trial
- Review
- Using updated clinical recommendations to support contraceptive decision-making: U.S. medical eligibility criteria for contraceptive use, 2024.Contraception · 2026Review
- Cardiovascular Safety of Hormonal Contraception: Method-Specific Risks and Clinical Implications.Medical sciences (Basel, Switzerland) · 2026Review
- Cardiovascular risk profile according to World Health Organization medical eligibility criteria for contraceptive use of women using hormonal contraception in Rio de Janeiro state, Brazil.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Article
- Hypertension in Women Across the Life Cycle: Unique Aspects and Challenges.Current hypertension reports · 2026Review
- Sex Hormone Supplementation and Cardiovascular Disease Risk.Medicina (Kaunas, Lithuania) · 2026Review
- Cardiometabolic, Glycaemic, and Metabolic Safety of Hormonal Contraceptives in Women with Medical Conditions: A Systematic Review.International journal of women's health · 2026Review
- Acute ST elevation myocardial infarction in a young female patient without cardiovascular risk factors-Massive left main coronary artery thrombosis induced by oral contraceptive pills: a case report.Journal of medical case reports · 2025Article
- Cross-sectional and longitudinal metabolomics-based profiles associated with oral contraceptive and progestin-only pill use: A Finnish population-based study.Acta obstetricia et gynecologica Scandinavica · 2025Article
- Behind the Headache: A Case of Cerebral Venous Thrombosis Associated With Hormonal Contraceptive Use.Cureus · 2025Article
- Evaluating the Efficacy and Safety of 48-Week Low-Dose Dienogest Administration in Patients With Dysmenorrhea Caused by Endometriosis: Protocol for a Randomized, Open-Label, Parallel-Group Trial.JMIR research protocols · 2025Article
- Moderate Associations Between the Use of Levonorgestrel-releasing Intrauterine Device and Metabolomics Profile.The Journal of clinical endocrinology and metabolism · 2025Article
- Anamnesis Checklist for Informed Oral Contraceptive Choices: A Spanish Perspective.Women's health reports (New Rochelle, N.Y.) · 2025Article
- Disease severity drives risk of venous thrombotic events in women with sickle cell disease in a single-center retrospective study.Research and practice in thrombosis and haemostasis · 2024Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Aims The association between progestin-only contraceptive (POC) use and the risk of various cardiometabolic outcomes has rarely been studied. We performed a systematic review and meta-analysis to determine the impact of POC use on cardiometabolic outcomes including venous thromboembolism, myocardial infarction, stroke, hypertension and diabetes. Methods and results Nineteen observational studies (seven cohort and 12 case-control) were included in this systematic review. Of those, nine studies reported the risk of venous thromboembolism, six reported the risk of myocardial infarction, six reported the risk of stroke, three reported the risk of hypertension and two studies reported the risk of developing diabetes with POC use. The pooled adjusted relative risks (RRs) for venous thromboembolism, myocardial infarction and stroke for oral POC users versus non-users based on the random effects model were 1.06 (95% confidence interval (CI) 0.70-1.62), 0.98 (95% CI 0.66-1.47) and 1.02 (95% CI 0.72-1.44), respectively. Stratified analysis by route of administration showed that injectable POC with a RR of 2.62 (95% CI 1.74-3.94), but not oral POCs (RR 1.06, 95% CI 0.7-1.62), was associated with an increased risk of venous thromboembolism. A decreased risk of venous thromboembolism in a subgroup of women using an intrauterine levonorgestrel device was observed with a RR of 0.53 (95% CI 0.32-0.89). No effect of POC use on blood pressure was found, but there was an indication for an increased risk of diabetes with injectable POCs, albeit non-significant. Conclusions This systematic review and meta-analysis suggests that oral POC use is not associated with an increased risk of developing various cardiometabolic outcomes, whereas injectable POC use might increase the risk of venous thromboembolism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.